False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation
Artificial Organs · 09.11.2026
DOI: 10.1111/aor.70282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, online erschienen am 09.11.2026. Verfasst von Chae Rin Im und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Royal Papworth Hospital, Cambridge, UK. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
False‐positive hepatitis C virus (HCV) (FPHC) serology has been reported with earlier‐generation axial‐flow left ventricular assist devices (LVADs), but its frequency with the magnetically levitated HeartMate 3 and its implications for heart transplant pathways remain unknown. This study describes FPHC serology in HeartMate 3 LVAD recipients and explores associated clinical and immunological features.
Methods
A retrospective, single‐center study was conducted at a specialist cardiothoracic center. All adults implanted with a HeartMate 3 LVAD between March 2018 and July 2025 with complete HCV serology before and after implantation were included. Patients developing HCV antibody positivity with negative confirmatory testing were classified as having FPHC serology. Patient demographics, blood product transfusions, liver function tests, lactate dehydrogenase, and human leukocyte antigen (HLA) sensitization were compared between groups.
Results
Among 54 HeartMate 3 LVAD recipients, 10 (18.5%) developed FPHC serology after implantation. There were no significant differences between groups in age, sex, liver function tests, or lactate dehydrogenase. The number of fresh frozen plasma units transfused at implantation and the development of anti‐HLA Class I antibodies were associated with FPHC serology ( p = 0.039, p = 0.04, respectively). No significant associations were observed with red blood cell or platelet transfusions.
Conclusion
FPHC serology is a clinically important phenomenon in HeartMate 3 LVAD recipients. Clinicians and patients should be aware of this phenomenon to minimize unnecessary investigations and delays to transplant candidacy assessment. Standardized confirmatory testing protocols and multicenter studies are needed to clarify the underlying immune mechanisms and their impact on post‐transplant outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology, Royal Papworth Hospital, Cambridge, UK.
- Transplant Unit, Royal Papworth Hospital, Cambridge, UK.
- Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital, Cambridge, UK.
ORCID-Profile: Chae Rin Im, Olly Allen, Marius Berman, Stephen Pettit
Zitieren
APA
Im, C. R., Allen, O., Kappeler, A. R. M., Pai, S., Pocock, J., Bhagra, S., Berman, M., Lincoln, P., Smith, C., & Pettit, S. (2026). False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation. Artificial Organs. https://doi.org/10.1111/aor.70282
Vancouver
Im CR, Allen O, Kappeler ARM, Pai S, Pocock J, Bhagra S, et al. False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation. Artificial Organs. 2026. doi:10.1111/aor.70282
BibTeX
@article{Im2026,
author = {Im, Chae Rin and Allen, Olly and Kappeler, A Ruth M and Pai, Sumita and Pocock, Jo and Bhagra, Sai and Berman, Marius and Lincoln, Paul and Smith, Chris and Pettit, Stephen},
title = {False‐Positive Hepatitis C Virus Serology Following HeartMate 3 Left Ventricular Assist Device Implantation},
journal = {Artificial Organs},
year = {2026},
doi = {10.1111/aor.70282}
}
EUVIMED